TScan Therapeutics (NASDAQ:TCRX) announced a strategic reorganization that includes a workforce reduction of approximately 75% as the company redirects resources toward an in vivo-engineered T cell receptor, or TCR-T, program targeting solid tumors.
The Waltham, Massachusetts-based company plans to advance two product candidates into investigational new drug-enabling studies. One candidate targets PRAME and the other targets MAGE-A4.
TScan expects to present preclinical data in the first quarter of 2027, submit its first investigational new drug application in the third quarter of 2027 and begin Phase 1 development in the fourth quarter of 2027.
These timelines represent company expectations and remain subject to development and regulatory processes.
Restructuring Expected to Save $55 Million Through 2027
TScan expects the reorganization to generate cumulative cost savings of approximately $55 million through the end of 2027.
The company said its cash, cash equivalents and marketable securities as of June 30, 2026 are expected to fund operations into the fourth quarter of 2027.
As part of the restructuring, TScan is eliminating its internal manufacturing organization and reducing its research operations.
The projected savings and cash runway represent management estimates and could change depending on future spending, development activities and other business conditions.
TScan Pauses Enrollment in Phase 3 ALLOHA-2 Study
TScan is also pausing further enrollment in its Phase 3 ALLOHA-2 study of TSC-101, which is being evaluated for hematologic malignancies.
The company cited insufficient capital to complete the trial.
Seven patients who have already been enrolled in the treatment arm will continue to be monitored.
TScan said it is actively seeking strategic partners to support further development of its hematologic malignancies program. The availability and terms of any future partnership have not been established.
ALLOHA Cohort C Data Show Complete Donor Chimerism in 13 Patients
TScan also provided updated data from Cohort C of its Phase 1 ALLOHA study.
According to the company, all 13 patients currently being followed demonstrated complete donor chimerism, including two patients who had previously relapsed.
TScan plans to report additional Cohort C data in the fourth quarter of 2026. The company also expects to provide data in the second quarter of 2027 covering all patients treated using its commercial-ready manufacturing process.
The reported findings represent current clinical data from the study and do not establish future clinical or regulatory outcomes.
TScan Evaluates Partnerships for Autoimmune Program
Alongside the changes to its oncology programs, TScan is evaluating potential strategic partnerships for its autoimmune program.
The program focuses on disorders associated with HLA-B*27, including ankylosing spondylitis.
“We have made the difficult decision to allocate our resources to programs we believe better allow us to create value for all stakeholders,” said Gavin MacBeath, Ph.D., Chief Executive Officer, in a statement based on the company’s press release.
The restructuring concentrates TScan’s internal resources on its in vivo-engineered TCR-T candidates for solid tumors while the company seeks external partners for other areas of its pipeline.